triheptanoin has been researched along with Cardiomyopathies in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bedrosian, CL; Enns, GM; Lu, X; Marsden, D; Rahman, S; Ramirez, AN; Ray, K; Reineking, B; Vockley, J | 1 |
| Berry, G; Burton, B; Cataldo, J; Chapman, K; Grunewald, S; Longo, N; Lu, X; Murphy, E; Phillips, J; Sanchez-Valle, A; Tanpaiboon, P; Vockley, J | 1 |
| Burchill, LJ; DeLany, JP; Deward, S; El-Gharbawy, AH; Gillingham, MB; Goldstein, A; Goodpaster, B; Harding, CO; Heitner, SB; Lasarev, MR; Martin, J; Matern, D; Pollaro, J; Rose, S; Shoemaker, J; Vockley, J | 1 |
| Abdenur, JE; Charrow, J; Conway, R; Diaz, GA; Enns, GM; Eswara, M; Ganesh, J; Marsden, DL; McCracken, E; Sanchez-de-Toledo, J; Starr, J; Vockley, J; Wang, R | 1 |
| Beermann, F; Behringer, S; Floegel, U; Spiekerkoetter, U; Tucci, S | 1 |
2 trial(s) available for triheptanoin and Cardiomyopathies
| Article | Year |
|---|---|
Effects of triheptanoin (UX007) in patients with long-chain fatty acid oxidation disorders: Results from an open-label, long-term extension study.
Topics: Adolescent; Adult; Cardiomyopathies; Child; Child, Preschool; Fatty Acids; Female; Humans; Hypoglycemia; Infant; Lipid Metabolism, Inborn Errors; Male; Middle Aged; Oxidation-Reduction; Rhabdomyolysis; Triglycerides; United Kingdom; United States; Young Adult | 2021 |
Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial.
Topics: Acyl-CoA Dehydrogenase, Long-Chain; Adolescent; Adult; Caprylates; Cardiomyopathies; Carnitine; Child; Dietary Fats; Double-Blind Method; Exercise; Fatty Acids; Female; Humans; Lipid Metabolism, Inborn Errors; Male; Middle Aged; Mitochondrial Myopathies; Mitochondrial Trifunctional Protein; Nervous System Diseases; Oxidation-Reduction; Rhabdomyolysis; Triglycerides; Young Adult | 2017 |
3 other study(ies) available for triheptanoin and Cardiomyopathies
| Article | Year |
|---|---|
Response to triheptanoin therapy in critically ill patients with LC-FAOD: Report of patients treated through an expanded access program.
Topics: Cardiomyopathies; Critical Illness; Fatty Acids; Humans; Infant; Lipid Metabolism, Inborn Errors; Oxidation-Reduction; Retrospective Studies; Stroke Volume; Triglycerides; Ventricular Function, Left | 2022 |
Triheptanoin treatment in patients with pediatric cardiomyopathy associated with long chain-fatty acid oxidation disorders.
Topics: Adolescent; Cardiomyopathies; Child; Child, Preschool; Clinical Trials as Topic; Energy Metabolism; Fatty Acids; Female; Humans; Infant; Infant, Newborn; Lipid Metabolism, Inborn Errors; Male; Oxidation-Reduction; Triglycerides | 2016 |
Triheptanoin: long-term effects in the very long-chain acyl-CoA dehydrogenase-deficient mouse.
Topics: Acyl-CoA Dehydrogenase, Long-Chain; Animals; Cardiomyopathies; Energy Metabolism; Fatty Acids; Heptanoic Acids; Humans; Lipid Metabolism, Inborn Errors; Liver; Mice; Oxidation-Reduction; Oxidative Stress; Triglycerides | 2017 |